Category Archives: Market Access

Challenges to the Specialty Business Model

By Emily O’Connor, Jillian Scaife, and Ryan P. Million Biopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations. However, the specialty business model has lately shown signs of strain and outright constraints in continued scalability. Agents such as Gleevec, Zaltrap, and Sovaldi have been under fire from […]
Also posted in Biotech, Strategy | Tagged , , , | Leave a comment

Pharma in Brunei: Growth Potential

Brunei is harnessing its rich biodiversity and the growing halal market in a bid to develop its pharmaceutical sector, writes Pharmaceutical Technology’s  Jane Wan. Though the Bruneian pharmaceutical sector is in its infancy, it possesses huge potential for growth and development. According to Business Monitor International (BMI), the sector is valued at US$100 million in 2013 […]
Also posted in Global | Tagged , , , , | Leave a comment

What Does ‘Off Label’ Mean in 2014?

by Tom Norton Years ago, while sitting in an Rx company lunch room, I was listening to one of the company’s top sales reps discuss the commercial progress a recently launched prescription was making. The rep said that the product was selling “OK” under its FDA approved, indicated therapeutic area. However, he quietly said, “It’s […]
Also posted in Biotech, FDA, Guest Blog, healthcare, Legal, Marketing, pricing, Regulatory, Strategy | Tagged , , | 1 Comment

Obamacare's "Unacceptable" Rx Copays

by Tom Norton We are now approaching the six month point in the implementation of the new Obamacare program. It’s senseless to go into the good, bad and ugly of this new program. While much of the concept continues to be thrashed about in the political arena, in terms of actual medical results the truth […]
Also posted in Biotech, Guest Blog, healthcare, leadership, Legal, Strategy | Tagged , , , , , , , | 2 Comments

Paying for the Future of Medicine

Is the hallmark of innovation higher drug prices? The three leading justifications for sticker-shocking drug prices in the US, from the biopharma perspective, are: 1) it costs a lot to bring a drug to market;* 2) drugs – even very expensive ones – are cheaper in the long run since they prevent complications, hospitalizations and […]
Also posted in Biotech, FDA, healthcare, leadership, Manufacturing, pricing, R&D, Regulatory, Technology | Tagged , , , , , , | 1 Comment
  • Categories

  • Meta